Novel Biomarkers and Liver Cancer
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Gastrointestinal Oncology".
Deadline for manuscript submissions: 15 January 2025 | Viewed by 891
Special Issue Editors
Interests: long non-coding RNA; signal transduction; liver cancer; extracellular vesicles; transcription regulation
Interests: hepatocellular carcinoma; cholangiocarcinoma; cell plasticity; TGFβ signaling; circular RNA
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Liver cancer, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), is one of the main causes of cancer-related deaths, with an increasing incidence and mortality over recent years. Controlling liver cancer progression is a laborious task, due to its asymptomatic nature in the early stages of the disease. For advanced HCC, chemotherapeutic drugs, such as sorafenib and lenvatinib, have been widely used, resulting in the modest improvement of patients’ life expectancy, accompanied by serious side effects. Recently, immunotherapy has been established as a new line of treatment for HCC; however, only some patients efficiently respond to it. Therefore, the identification of novel molecules that can serve as diagnostic or prognostic biomarkers is of paramount importance.
In this Special Issue, we invite researchers and clinicians to publish original research articles or reviews within the scope of liver cancer biomarker identification that could potentially contribute to improved prognoses and enhance the prediction of therapy response.
We look forward to receiving your contributions.
Dr. Panagiotis Papoutsoglou
Dr. Cédric Coulouarn
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- biomarker
- hepatocellular carcinoma
- cholangiocarcinoma
- prognosis
- therapy response
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
